Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Araim Pharmaceuticals, Inc. · Neuropathy of Sarcoidosis
Phase 2
Completed
64
2017-04
Evidence dashboardStudies since 2012Updated Jul 31, 2026
ARA-290 / CibinetideClinical Trials.
A source-linked view of every ARA-290 / Cibinetide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 4
- Recruiting
- 0
- Completed
- 2
- Terminated
- 1
- Results posted
- 1
- Average enrollment
- 33
- Countries
- 4
- Highest phase
- Phase 2
Largest indexed study
64 participants · NCT02039687 →Developer / research origin
Araim Pharmaceuticals
Evidence summary
Activity is not efficacy.
ARA-290 / Cibinetide appears in 4 indexed studies: 0 recruiting, 2 completed and 1 with registry results posted. The highest registered development stage in this snapshot is Phase 2. These counts measure registry activity; they do not establish that ARA-290 / Cibinetide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
No studies in this snapshot.
NCT IDStudyPhase / statusEnrollmentUpdated
Cognitive and Neural Effects of ARA290
Leiden University Medical Center · Depression
Phase 1 / Phase 2
Completed
36
2014-02
NCT IDStudyPhase / statusEnrollmentUpdated
The Use of ARA290 for the Treatment of Diabetic Macular Oedema
Belfast Health and Social Care Trust · Diabetic Macular Oedema
Phase 2
Terminated
9
2024-10
Full study index
Search ARA-290 / Cibinetide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
4 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 19017170 ↗Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008 Nov;264(5):405-32. doi: 10.1111/j.1365-2796.2008.02024.x.Linked from NCT02070783PMID 21947319 ↗Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl). 2012 Feb;219(3):687-98. doi: 10.1007/s00213-011-2511-1. Epub 2011 Sep 23.Linked from NCT02070783PMID 26431906 ↗Cerit H, Veer IM, Dahan A, Niesters M, Harmer CJ, Miskowiak KW, Rombouts SA, Van der Does W. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. Eur Neuropsychopharmacol. 2015 Dec;25(12):2289-99. doi: 10.1016/j.euroneuro.2015.09.005. Epub 2015 Sep 18.Linked from NCT02070783
Related pages
Keep researching ARA-290 / Cibinetide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.